{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:12:19Z","timestamp":1782299539196,"version":"3.54.5"},"reference-count":17,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>The advent of multiplexed bead assays in recent years has introduced a new dimension of testing for complex diseases such as lupus, which can involve multiple autoantibodies. The ability to rapidly identify multiple autoantibodies, with high sensitivity and specificity in an automated fashion, is highly attractive. The aim of this study was to assess the performance and clinical value of multiplexed bead-based (AtheNA Multi-Lyte ANA-II test system) immunoassays both by comparing the results with those achieved by indirect fluorescent-antibody assay (IFA) or conventional enzyme immunoassays (EIAs) and by independent identification of autoantibodies in well-characterized samples. To achieve this goal, 984 samples were tested for seven analytes (SS\/A, SS\/B, Sm, RNP, Scl-70, double-stranded DNA [dsDNA], and centromere B) in both traditional and bead-based assays. The average concordance for the different analytes was 91%, ranging from 81% (dsDNA) to 97% (centromere B). The average relative specificity and sensitivity for the analytes were also high, 92% and 81%, respectively. An examination of 93 \u201cnormal controls\u201d demonstrated a 7% false-positive rate, which was comparable to IFA. Percentages of different autoantibodies found in patients with a variety of disease conditions (34 with calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia; 41 with mixed connective tissue disease; 24 with scleroderma; and 35 with Sjogren's syndrome) were well within the range expected from each group. A scrutiny of results from AtheNA and EIA and Farr results for 185 systemic lupus erythematosus samples revealed comparable results by both methods, with the exception of SS\/A and dsDNA, where AtheNA had a higher percentage of SS\/A-positive results compared to EIA (51% versus 29%) and a lower percentage of dsDNA-positive results (18% versus 28% at a cutoff of 5 IU\/ml).<\/jats:p>","DOI":"10.1128\/cvi.00034-07","type":"journal-article","created":{"date-parts":[[2007,3,22]],"date-time":"2007-03-22T00:38:46Z","timestamp":1174523926000},"page":"505-509","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":35,"title":["Clinical Value of Multiplexed Bead-Based Immunoassays for Detection of Autoantibodies to Nuclear Antigens"],"prefix":"10.1128","volume":"14","author":[{"given":"Erik","family":"Avaniss-Aghajani","sequence":"first","affiliation":[{"name":"Primex Clinical Laboratories, Inc., 16742 Stagg St. #120, Van Nuys, California 91406"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Berzon","sequence":"additional","affiliation":[{"name":"Primex Clinical Laboratories, Inc., 16742 Stagg St. #120, Van Nuys, California 91406"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlen","family":"Sarkissian","sequence":"additional","affiliation":[{"name":"Primex Clinical Laboratories, Inc., 16742 Stagg St. #120, Van Nuys, California 91406"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"1155","volume":"42","year":"2004","unstructured":"Bernardini, S., M. Infantino, L. Bellincampi, M. Nuccetelli, A. Afeltra, R. Lori, A. Biroccio, A. Urbani, and G. Federici. 2004. Screening of antinuclear antibodies: comparison between enzyme immunoassay based on nuclear homogenates, purified or recombinant antigens and immunofluorescence assay. Clin. Chem. Lab. Med.42:1155-1160.","journal-title":"Clin. Chem. Lab. Med."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/art.1780400910","volume":"40","year":"1997","unstructured":"Emlen, W., and L. O'Neil. 1997. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum.40:1612-1618.","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_4_2","first-page":"1267","volume":"32","year":"2005","unstructured":"Faria, A. C., K. S. Barcellos, and L. E. Andrade. 2005. Longitudinal fluctuation of antibodies to extractable nuclear antigens in systemic lupus erythematosus. J. Rheumatol.32:1267-1272.","journal-title":"J. Rheumatol."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/infdis\/103.3.239","volume":"103","year":"1958","unstructured":"Farr, R. S. 1958. A quantitative immunochemical measure of the primary interaction between I BSA and antibody. J. Infect. Dis.103:239-262.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_6_2","first-page":"2179","volume":"68","year":"2003","unstructured":"Gill, J. M., A. M. Quisel, P. V. Rocca, and D. T. Walters. 2003. Diagnosis of systemic lupus erythematosus. Am. Fam. Physician68:2179-2186.","journal-title":"Am. Fam. Physician"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/clinchem\/43.10.1987","volume":"43","year":"1997","unstructured":"Gniewek, R. A., C. Sandbulte, and P. C. Fox. 1997. Comparison of antinuclear antibody testing methods by ROC analysis with reference to disease diagnosis. Clin. Chem.43:1987-1989.","journal-title":"Clin. Chem."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.4.2.185-188.1997"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0009-9120(02)00342-9","volume":"35","year":"2002","unstructured":"Gonzalez, C., P. Guevara, I. Alarcon, M. Hernando, J. A. Navajo, and J. M. Gonzalez-Buitrago. 2002. Antinuclear antibodies (ANA) screening by enzyme immunoassay with nuclear HEp-2 cell extract and recombinant antigens: analytical and clinical evaluation. Clin. Biochem.35:463-469.","journal-title":"Clin. Biochem."},{"key":"e_1_3_2_10_2","first-page":"1960","year":"2005","unstructured":"Hahn, B. H. 2005. Systemic lupus erythematosus, p. 1960-1967. In D. Kasper (ed.), Harrison's principles of internal medicine, 16th ed. McGraw-Hill, New York, NY.","journal-title":"Harrison's principles of internal medicine"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/ajcp\/105.4.468","volume":"105","year":"1996","unstructured":"Jaskowski, T. D., C. Schroder, T. B. Martins, C. L. Mouritsen, C. M. Litwin, and H. R. Hill. 1996. Screening for antinuclear antibodies by enzyme immunoassay. Am. J. Clin. Pathol.105:468-473.","journal-title":"Am. J. Clin. Pathol."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5858\/2000-124-0071-GFCUOT","volume":"124","year":"2000","unstructured":"Kavanaugh, A., R. Tomar, J. Reveille, D. H. Solomon, and H. A. Homburger. 2000. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. Arch. Pathol. Lab. Med.124:71-81.","journal-title":"Arch. Pathol. Lab. Med."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1128\/CDLI.11.6.1054-1059.2004","volume":"11","year":"2004","unstructured":"Martins, T. B., R. Burlingame, C. A. von Muhlen, T. D. Jaskowski, C. M. Litwin, and H. R. Hill. 2004. Evaluation of multiplexed fluorescent microsphere immunoassay for detection of autoantibodies to nuclear antigens. Clin. Diagn. Lab. Immunol.11:1054-1059.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_14_2","first-page":"729","volume":"18","year":"2000","unstructured":"Morozzi, G., F. Bellisai, A. Simpatico, G. Pucci, M. R. Bacarelli, V. Campanella, R. Marcolongo, and M. Galeazzi. 2000. Comparison of different methods for the detection of anti-Ro\/SSA antibodies in connective tissue diseases. Clin. Exp. Rheumatol.18:729-731.","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1196\/annals.1313.120","volume":"1050","year":"2005","unstructured":"Shovman, O., B. Gilburd, O. Barzilai, E. Shinar, B. Larida, G. Zandman-Goddard, S. R. Binder, and Y. Shoenfeld. 2005. Evaluation of the BioPlex(tm) 2200 ANA screen. Analysis of 510 healthy subjects: incidence of natural\/predictive autoantibodies. Ann. N. Y. Acad. Sci.1050:380-388.","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/art.1780400909","volume":"40","year":"1997","unstructured":"Tan, E. M., T. E. Feltkamp, J. S. Smolen, B. Butcher, R. Dawkins, M. J. Fritzler, T. Gordon, J. A. Hardin, J. R. Kalden, R. G. Lahita, R. N. Maini, J. S. McDougal, N. F. Rothfield, R. J. Smeenk, Y. Takasaki, A. Wiik, M. R. Wilson, and J. A. Koziol. 1997. Range of antinuclear antibodies in \u201chealthy\u201d individuals. Arthritis Rheum.40:1601-1611.","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/art.20229","volume":"51","year":"2004","unstructured":"Wiik, A. S., T. P. Gordon, A. F. Kavanaugh, R. G. Lahita, W. Reeves, W. J. van Venrooij, M. R. Wilson, and M. Fritzler. 2004. Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthritis Rheum.51:291-298.","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1084\/jem.20042251","volume":"201","year":"2005","unstructured":"Yurasov, S., H. Wardemann, J. Hammersen, M. Tsuiji, E. Meffre, V. Pascual, and M. C. Nussenzweig. 2005. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med.201:703-711.","journal-title":"J. Exp. Med."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00034-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00034-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:38:05Z","timestamp":1627591085000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00034-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1128\/CVI.00034-07"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00034-07","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"2007-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-03-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}